debrisoquin

Also known as Debrisochinum, Debrisoquine, Isocaramidine, Debrisoquina, Debrisoquinum, Debrisoquin sulfate, 1,2,3,4-tetrahydroisoquinoline-2-carboximidamide

Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug-metabolizing enzyme.

Research

1,496 papers

Substrate specificity of CYP2D6 genetic variants.Pharmacogenomics · 2021
[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].L'Encephale · 1986
The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.Pharmacology & therapeutics · 1990
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.Clinical pharmacology and therapeutics · 2001
New drugs in hypertension.Canadian Medical Association journal · 1977

via PubMed

Article

2 sections

Contents

See also
References

Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug-metabolizing enzyme.

Debrisoquine has been identified as a inhibitor of TMPRSS2 protease, which is involved in the viral entry process of SARS-CoV-2. In a laboratory study, it showed antiviral activity by blocking the ability of the virus to enter human lung cells.